GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (NAS:AKRO) » Definitions » PB Ratio

Akero Therapeutics (Akero Therapeutics) PB Ratio : 2.05 (As of May. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Akero Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-13), Akero Therapeutics's share price is $19.65. Akero Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $9.60. Hence, Akero Therapeutics's PB Ratio of today is 2.05.

The historical rank and industry rank for Akero Therapeutics's PB Ratio or its related term are showing as below:

AKRO' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 11.46
Current: 2.05

During the past 7 years, Akero Therapeutics's highest PB Ratio was 11.46. The lowest was 0.00. And the median was 0.00.

AKRO's PB Ratio is ranked better than
57.12% of 1313 companies
in the Biotechnology industry
Industry Median: 2.48 vs AKRO: 2.05

During the past 12 months, Akero Therapeutics's average Book Value Per Share Growth Rate was 37.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 8.80% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Akero Therapeutics was 15.60% per year. The lowest was 8.80% per year. And the median was 12.20% per year.

Back to Basics: PB Ratio


Akero Therapeutics PB Ratio Historical Data

The historical data trend for Akero Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics PB Ratio Chart

Akero Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 4.93 3.46 4.37 7.86 2.43

Akero Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.86 5.87 4.21 4.83 2.43

Competitive Comparison of Akero Therapeutics's PB Ratio

For the Biotechnology subindustry, Akero Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akero Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's PB Ratio falls into.



Akero Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Akero Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=19.65/9.601
=2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Akero Therapeutics  (NAS:AKRO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Akero Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akero Therapeutics (Akero Therapeutics) Business Description

Traded in Other Exchanges
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Executives
Jonathan Young officer: Chief Operating Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FL, SOUTH SAN FRANCISCO CA 94080
Andrew Cheng director, officer: President & CEO 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Catriona Yale officer: Chief Development Officer C/O AKERO THERAPEUTICS INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
William Richard White officer: Chief Financial Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy Rolph officer: Chief Scientific Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Patrick Lamy officer: See Remarks AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Skorpios Trust other: Former 10% owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd other: Former 10% owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd other: Former 10% owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd other: Former 10% owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Seth Loring Harrison director 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Chou Judy director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO CA 64080